188 related articles for article (PubMed ID: 33238856)
1. The Anticancer Activity of Indazole Compounds: A Mini Review.
Shang C; Hou Y; Meng T; Shi M; Cui G
Curr Top Med Chem; 2021; 21(5):363-376. PubMed ID: 33238856
[TBL] [Abstract][Full Text] [Related]
2. Indazole Derivatives: Promising Anti-tumor Agents.
Wan Y; He S; Li W; Tang Z
Anticancer Agents Med Chem; 2018; 18(9):1228-1234. PubMed ID: 29745343
[TBL] [Abstract][Full Text] [Related]
3. Indazole derivatives and their therapeutic applications: a patent review (2013-2017).
Denya I; Malan SF; Joubert J
Expert Opin Ther Pat; 2018 Jun; 28(6):441-453. PubMed ID: 29718740
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in the Development of Indazole-based Anticancer Agents.
Dong J; Zhang Q; Wang Z; Huang G; Li S
ChemMedChem; 2018 Aug; 13(15):1490-1507. PubMed ID: 29863292
[TBL] [Abstract][Full Text] [Related]
5. Recent Development of Heterocyclic Compounds with Indazole Moiety as Potential Antiparasitic Agents.
Paul A; Guria T; Roy P; Maity A
Curr Top Med Chem; 2022; 22(14):1160-1176. PubMed ID: 35473547
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of indazole derivatives: recent developments.
Cerecetto H; Gerpe A; González M; Arán VJ; de Ocáriz CO
Mini Rev Med Chem; 2005 Oct; 5(10):869-78. PubMed ID: 16250831
[TBL] [Abstract][Full Text] [Related]
7. Indazole as a Privileged Scaffold: The Derivatives and their Therapeutic Applications.
Qin J; Cheng W; Duan YT; Yang H; Yao Y
Anticancer Agents Med Chem; 2021; 21(7):839-860. PubMed ID: 32819234
[TBL] [Abstract][Full Text] [Related]
8. Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
Govek SP; Nagasawa JY; Douglas KL; Lai AG; Kahraman M; Bonnefous C; Aparicio AM; Darimont BD; Grillot KL; Joseph JD; Kaufman JA; Lee KJ; Lu N; Moon MJ; Prudente RY; Sensintaffar J; Rix PJ; Hager JH; Smith ND
Bioorg Med Chem Lett; 2015 Nov; 25(22):5163-7. PubMed ID: 26463130
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors.
Henke MM; Richly H; Drescher A; Grubert M; Alex D; Thyssen D; Jaehde U; Scheulen ME; Hilger RA
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):58-60. PubMed ID: 19203540
[No Abstract] [Full Text] [Related]
10. Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines.
Zhao CR; Wang RQ; Li G; Xue XX; Sun CJ; Qu XJ; Li WB
Bioorg Med Chem Lett; 2013 Apr; 23(7):1989-92. PubMed ID: 23454017
[TBL] [Abstract][Full Text] [Related]
11. Rational drug design of indazole-based diarylurea derivatives as anticancer agents.
Chu YY; Cheng HJ; Tian ZH; Zhao JC; Li G; Chu YY; Sun CJ; Li WB
Chem Biol Drug Des; 2017 Oct; 90(4):609-617. PubMed ID: 28338292
[TBL] [Abstract][Full Text] [Related]
12. A review on synthetic strategy, molecular pharmacology of indazole derivatives, and their future perspective.
Mal S; Malik U; Mahapatra M; Mishra A; Pal D; Paidesetty SK
Drug Dev Res; 2022 Nov; 83(7):1469-1504. PubMed ID: 35971890
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Activity Evaluation of Nasopharyngeal Carcinoma Inhibitors Based on 6-(Pyrimidin-4-yl)-1H-indazole.
Liao B; Peng L; Zhou J; Mo H; Zhao J; Yang Z; Guo X; Zhang P; Zhang X; Zhu Z
Chem Biodivers; 2019 May; 16(5):e1800598. PubMed ID: 30788913
[TBL] [Abstract][Full Text] [Related]
14. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Cognetti F
Drugs Today (Barc); 2003 Mar; 39(3):157-74. PubMed ID: 12730701
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in Indazole-Containing Derivatives: Synthesis and Biological Perspectives.
Zhang SG; Liang CG; Zhang WH
Molecules; 2018 Oct; 23(11):. PubMed ID: 30373212
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of N-substituted indazole-3-carboxamides as poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors(†).
Patel MR; Pandya KG; Lau-Cam CA; Singh S; Pino MA; Billack B; Degenhardt K; Talele TT
Chem Biol Drug Des; 2012 Apr; 79(4):488-96. PubMed ID: 22177599
[TBL] [Abstract][Full Text] [Related]
17. The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo.
Cui YJ; Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2020 Feb; 187():111968. PubMed ID: 31865012
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of indazole motifs and their medicinal importance: an overview.
Gaikwad DD; Chapolikar AD; Devkate CG; Warad KD; Tayade AP; Pawar RP; Domb AJ
Eur J Med Chem; 2015 Jan; 90():707-31. PubMed ID: 25506810
[TBL] [Abstract][Full Text] [Related]
19. Phase I toxicologic study of Lonidamine in cancer patients.
Band PR; Deschamps M; Besner JG; Leclaire R; Gervais P; De Sanctis A
Oncology; 1984; 41 Suppl 1():56-9. PubMed ID: 6717896
[TBL] [Abstract][Full Text] [Related]
20. Indazole and its Derivatives in Cardiovascular Diseases: Overview, Current Scenario, and Future Perspectives.
Uppulapu SK; Alam MJ; Kumar S; Banerjee SK
Curr Top Med Chem; 2022; 22(14):1177-1188. PubMed ID: 34906057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
